Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease

Takeru Asano, Ken Ichi Matsuoka, Satoshi Iyama, Kazuteru Ohashi, Yoshihiro Inamoto, Chikako Ohwada, Makoto Murata, Atsushi Satake, Chikamasa Yoshida, Koichi Nakase, Yasuo Mori, Mitsune Tanimoto

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Chronic graft versus host disease (cGVHD) remains a major problem for long survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Currently, corticosteroid therapy is effective for cGVHD as the first line therapy. However, prolonged therapy with corticosteroids causes various severe adverse events. To develop the new therapeutic strategy of cGVHD, we have launched a multicenter phase I/IIa clinical trial of low dose subcutaneous interleukin-2 (IL-2) for treatment of steroid refractory cGVHD, which is constituted of 2 sequential phases (induction phase and maitanance phase). This study will provide the new therapeutic option for patients with refractory cGVHD after allogeneic HSCT.

Original languageEnglish
Pages (from-to)429-433
Number of pages5
JournalActa medica Okayama
Volume70
Issue number5
Publication statusPublished - 2016

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease'. Together they form a unique fingerprint.

Cite this